Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelpultide alfa - Airway Therapeutics

Next Previous
Drug Profile

Zelpultide alfa - Airway Therapeutics

Alternative Names: AT-100; rhSP-D

Latest Information Update: 21 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Airway Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antivirals; Recombinant proteins
  • Mechanism of Action Cell membrane permeability enhancers; Protein replacements; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bronchopulmonary dysplasia
  • Phase I COVID 2019 infections
  • Preclinical Adult respiratory distress syndrome; Asthma; Chronic obstructive pulmonary disease; Influenza virus infections; Respiratory syncytial virus infections
  • Research Inflammation; Respiration disorders

Most Recent Events

  • 12 Aug 2025 Airway Therapeutics plans a pivotal phase IIb/III trial for Bronchopulmonary Dysplasia (In infants, Prevention)
  • 12 Aug 2025 Airway Therapeutics plans to submit regulatory filings for Zelpultide alfa in Argentina, Australia, and USA
  • 12 Aug 2025 Airway Therapeutics plans to submit the PDCO-approved protocol to regulatory authorities in Italy (AIFA), Spain (AEMPS), and Israel (MoH), followed by France, Germany, Belgium, and Poland to initiate the phase IIb/III trial in Bronchopulmonary dysplasia (BPD) (In infants, Prevention) in late third or fourth quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top